Poster Session B
Wednesday, June 20
12:30 p.m.-2:30 p.m.

In alphabetical order, not board assignment order

• 3D MR imaging of ECM alterations in mouse model of pancreatic cancer (PC). Palamadai N. Venkatasubramanian, Paul J. Grippo, Gheorghe Iordanescu, Richard H. Knop, Alice M. Wyrwicz
• A diet high in fats and calories leads to obesity and metabolic disturbances and accelerates pancreatic cancer development in the conditional KrasG12D mouse model. Aune Moro, Aurelia Lugea, David Dawson, Steven Pandol, Anna Gukovskaya, Enrique Rozengurt, Vay-Liang Go, Guido Eibl
• A Disintegrin and Metalloproteinase 10 (ADAM10) regulates pancreatic cancer progression by accelerating tumorigenesis and metastasis. Jason Hall, Howard Crawford
• A genome-wide RNA interference screen identifies NUP62 as a context-dependent driver of pancreatic adenocarcinoma chemoreistance to gemcitabine. Mohamed Elhassan, Jennifer Christie, Mark Duxbury
• A modified p14ARF promoter linked to bicistronic p14 and t-BID induces synergistic apoptosis selectively in mutant ras and mutant p53 cancers in vitro and in vivo. Yuehua Mao, Richard D. Dinnen, Yong-Liang Li , Dario Garcia-Carracedo, Gloria Su, Paul Brandt-Rauf, Robert L. Fine
• A Molecular Pre-operative Prognostic Nomogram for Resectable Pancreatic Cancer. David K. Chang, Angela Chou, Nam Q. Nguyen, Adnan M. Nagrial, Lorraine A. Chantrill, Venessa T. Chin, Elizabeth A. Musgrove, Robert L. Sutherland, Anthony J. Gill, Sean Altekruse, James G. Kench, Christopher J. Scarlett, Andrew V. Biankin, Mark Pinese, Marina Pajic, Emily K. Colvin, Amber L. Johns, Jeremy L. Humphris, Jianmin Wu, Mark J. Cowley
• A prioritization pipeline for the identification of somatic driver aberrations in pancreatic cancer. Turgut Dogruluk, Armel Gifford, Marie-Calude Gingras, Kenneth L. Scott
• A randomized, open-label phase 2 trial of gemcitabine with or without bavituximab in patients with previously untreated stage IV pancreatic cancer. Shuchi Sumant Pandya, Lucas Wong, Tony R. Reid, Stephen A. Grabelsky, Merrill Kingman Shum, Kerstin B. Menander, Joseph Shan
• Acquired resistance of pancreatic cancer cells to 2-methoxyestradiol is associated with the upregulation of manganese superoxide dismutase in the mitochondria. Jianhong Zhou, Yuchun Du
• Activation of transforming growth factor β signaling (TGFβ) accelerates KrasG12D-driven pancreatic tumor initiation in mice. David F. Vincent, Lindsay Alcaraz, Johann Gout, Isabelle Treilleux, Ulrich Valcourt, Pierre Dubus, Laurent Bartholin
• An engineered chimeric, Fc-mutated, Anti-CA19-9 scFv-Fc for targeting pancreas cancer in an orthotopic model. Matthew M. Rochefort, Mark D. Girgis, Scott M. Knowles, James S. Tomlinson
• Analysis of the role of JNK and therapeutic effect of JNK inhibition on pancreatic cancer. Takahashi Ryota, Nakata Wachiko, Kinoshita Hiroto, Hayakawa Yoku, Nakagawa Hayato, Ijichi Hideaki, Hirata Yoshihiro, Maeda Shin, Koike Kazuhiko
• Anti-FZD antibody OMP-18R5 inhibits metastases in a murine orthotopic model of human pancreatic cancer. Pete Yeung, Wan-Chin Yen, Austin Gurney, John Lewicki, Ann M. Kapoun, Timothy Hoey, Lucia Beviglia
• Arousal of cancer-associated stromal fibroblasts: Palladin-activated fibroblasts promote tumor invasion. Teresa Averill Brentnall, Lisa Lai, Mary Bronner, Ru Chen
• Arsenic trioxide, ascorbic acid and disulfiram (AAA) arrests pancreatic cancer development in a transgenic mouse model with disrupted p16 activated Kras. Richard D. Dinnen, Wanglong Qiu, Yuehua Mao, Gloria Su, Robert Fine
• ATDC synergizes with oncogenic Kras to induce invasive pancreatic adenocarcinoma in transgenic mice. Lidong Wang, Huibin Yang, Filip Bednar, Yaqing Zhang, Jacob Leflein, Taylor Detzler, Gina M. Ney, Marina Pasca di Magliano, Diane M. Simeone
• Bmi1 is required for murine pancreatic cancer initiation. Filip Bednar, Yaqing Zhang, Daisuke Nakada, Diane M. Simeone, Sean J. Morrison, Marina Pasca di Magliano
• Brucein D Suppresses Pancreatic Tumor Growth in a Mouse Orthotopic Nude Model. Ling Liu, Zhi Xiu Lin, Po Sing Leung
• Cell survival in pancreatic cancer is regulated by glycosylation of the transcription factor Sp1. Sulagna Banerjee, Veena Sangwan, Olivia McGinn, Tara Kendall Krosch, Nameeta Mujumder, Vikas Dudeja, Mackenzie Tiffany, Vickers M. Selwyn, Ashok K Saluja
• Circulating cancer stem cells - a new target for treatment of pancreatic cancer?. Hermann Patrick, Jacob Insua, Mercedes Alonso, Christopher Heeschen
• Clonal Profiling of Prospectively Collected Primary Pancreatic Ductal Adenocarcinomas. Michael T. Barrett, Elizabeth Lenkiewicz, Lisa Evers, Tara Holley, Meraj Aziz, Edward Stites, Richard Posner, Amy Kramer, Jeffrey Drebin, Daniel D. Von Hoff
• Co-Targeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer. Terence M. Williams, Athena Flecha, Paul Keller, Ashwin Ram, David Karnak, Brian Ross, Theodore Lawrence, Alnawaz Rehemtulla, Judith Sebolt-Leopold
• Critical role of hemidesmosome breakdown for human pancreatic cancer cell migration and invasion. Séverine Laval, Mounira Chalabi, Hanane Laklai, Marjorie Fanjul, Hubert Lulka, Talal Al Saati, Marie-Bernadette Delisle, Stéphane Pyronnet, Corinne Bousquet
• Deciphering Mechanisms of p53-Mediated Pancreatic Cancer Suppression. Stephano Spano Mello, Colleen A. Brady, Dadi Jiang, Daniela Kenzelmann Broz, Eunice J. Park, Hannes Vogel, Laura D. Attardi
• Decreased expression of Disabled-2 correlates with epithelial-to-mesenchymal transition in pancreatic cancer. Barbara A Hocevar
• Depletion of antibodies and serum-derived proteins to facilitate LC-MS detection of pancreas-specific proteins in pancreatic ductal secretions. Jana D. Rocker, Carlo Contreras, Lee W. Thompson, Russell E. Brown , Jack A. DiPalma, Lewis K. Pannell
• Determining molecular and cellular mechanisms of Gemcitabine response and relapse using human PDAC xenograft models. Antreas A. Hindoyan, Linh Tran, Sindhuja Godavarthi, Daniel Braas, Heather Christofk, Timothy Donahue, Hong Wu
• Development of a high-throughput screen to identify oncogene mediated dependencies in transformed cancer cells. Maggie Martins, Sourav Bandyopadhyay
• Disruption of NFκB/Stat3 interaction as a potential therapeutic avenue for pancreatic cancer management. Jingjing Gong, Jianping Xie, Izhar Batth, James W. Freeman, Divya Chakravarthy, Addanki Pratap Kumar
• Drug-eluting microparticles for the treatment of pancreatic cancer: Preliminary in vivo results. Amon Asgharpour, Manoj Ganesh, Jing Ling, Albert Stanek, Wenchun Xie, Alicia Gooding, Sherif Andrawes, Richard Gross, Frank Gress, Laura Martello-Rooney
• EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Barbara M. Gruener, Clara Lubeseder-Martellato, Christine M. Ardito, Thomas Briel, Pawel K. Mazur, Schmid M. Roland, Howard C. Crawford, Jens T. Siveke
• EGFR activation by the ADAM17 sheddase is required for Kras induced pancreatic tumorigenesis. Christopher J. Halbrook, Kenneth K. Takeuchi, Christine M. Ardito, Barbara M. Gruener, Jens T. Siveke, Howard C. Crawford
• Elucidation of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma. Helene Damhofer, Maarten F. Bijlsma, Jan Paul Medema
• Enkephalin-encoding HSV-1 vectors demonstrate proinflammatory blunting and increased transgene met- and leu-enkephalin expression in cultured human pancreatic carcinoma cells - PANC-1. Terry A. McNearney, Huaizhi Yin, Steven P. Wilson, Karin N. Westlund
• Epigenetic silencing of DAZ interacting protein 1 in pancreatic ductal adenocarcinoma. Eileen O'Sullivan, Noriyuki Omura, Michael Goggins
• Epigenetic therapy and the tumor microenvironment in pancreatic cancer. Tamas Gonda, Reena Shakya, Michael Quante, Helen Remotti, Matthias Szabolcs, Timothy C. Wang, Thomas Ludwig, Benjamin Tycko
• Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced mitogen-activated protein kinase signal. Koji Miyabayashi, Hiroyuki Isayama, Masao Omata, Harold L. Moses, Kazuhiko Koike, Hideaki Ijichi, Dai Mohri, Motohisa Tada, Keisuke Yamamoto, Yoshinari Asaoka, Tsuneo Ikenoue, Keisuke Tateishi, Yousuke Nakai
• Evaluation of Src-mediated signaling events in pancreatic cancer. Leanna R. Gentry, Andrei V. Karginov, James J. Fiordalisi, Channing J. Der, Adrienne D. Cox
• Exosomal survivin, a potential tool for early detection of pancreatic cancer health disparity? Salma Khan, Jessica M.S. Jutzy , Jonathan R. Aspe, Nathan R. Wall
• Expression of ABC transporters in human pancreatic cancer cell lines and correlation with gemcitabine sensitivity. Li Pang, Beverly Word, Honggang Wang, Beverly Lyn-Cook
• Expression of KRASG12V and loss of Smad4 contribute to pancreatic duct cell carcinogenesis. Lisa Leung, Nikolina Radulovich, Chang J. Park, Christine To, Emin Ibrahimov, Bizhan Bandarchi, Ming-Sound Tsao
• Expression of microRNAs in pancreatic ductal adenocarcinoma cells. Amy Y.M. Au, Yi Wen Kong, Jennifer P. Morton, T.R. Jeff Evans, Martin Bushell, Owen Sansom
• FG-3019, a novel human monoclonal antibody to connective tissue growth factor, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. V.J. Picozzi, F. Valone, J.M. Pipas, A.C. Koong, A.J. Giaccia, K. Modelska, J. Chou, M. Zhong, S. Porter, T. Neff
• Fibroblast activation protein alpha expressing stromal cells mediate immune suppression in the KPC mouse model of pancreatic ductal adenocarcinoma. James O. Jones, Christine Feig, Edward W. Roberts, Richard J.B. Wells, David A. Tuveson, Douglas T. Fearon
• Gemcitabine induced interleukin-8 expression is a surrogate marker for effects on pancreatic ductal adenocarcinoma cells and is associated with tumor microenvironment remodeling. Thiruvengadam Arumugam, Takahiko Fujii, Huang Haojie, Rosa F. Hwang, Vijaya Ramachandran, Craig D. Logsdon
• Genomic analysis of pancreatic ductal adenocarcinoma. Christina K. Yung, Christine Ouellete, Lee Timms, Michelle Sam, Kimberly Begley, Thomas J. Hudson, John D. McPherson, Lincoln D. Stein, Timothy Beck, Lakshmi Muthuswamy, Richard De Borja, Carson Holt, Rob Denroche, Fouad Yousif, Zheng Zha, Niloofar Arshadi
• Genotype-selected biomarkers for the accurate diagnosis of pancreatic cancer. Huiyuan Tang, Katie Partyka, Kevin Maupin, Randall Brand, Brain Haab
• GLI-1 inhibitor suppresses self-renewal of pancreatic cancer stem cells. Yumi Miyazaki, Qiang Ding, Makoto Yoshimitsu, Koki Maeda, Taisaku Kuwahata, Toru Obara, Koichirou Tsukasa, Shuichiro Matsubara, Sonshin Takao
• Heterogeneity analysis of hypoxia in surgical samples of pancreatic cancer. Neesha C. Dhani, Stefano Serra, Joerg Schwock, Jing Xu, Melania Pintilie, Steven Gallinger, Richard Hill, David W. Hedley
• High efficacy of α-gal epitopes immune-based therapy against pancreatic cancer, using tumor cell lysates. Eiji Miyoshi, Masahiro Tanemura, Tsukasa Tanida, Takahiro Deguchi, Yuji Nonaka, Hiroaki Nagano, Masaki Mori, Yuichiro Doki
• HOXB7 modulates tumor cell invasion and is a predictor of poor clinical outcome in pancreatic cancer. Michael A. Arensman, Anne N. Kovochich, Timothy Donahue, Samuel W. French, David W. Dawson
• Identification of dysregulated pathways in pancreatic cancer through gene set and sub-network enrichment analyses of transcriptome and DNA methylome data. Jason Hoskins, Jinping Jia, Hemang Parikh, Irene Collins, Snorri Thorgeirsson, Ken Lo, Perwez Hussain, Gloria Petersen, Laufey Amundadottir
• Identification of serum biomarker signatures associated with pancreatic cancer. Anna Sandström, Christer Wingren, Ralf Segersvärd, Anders Carlsson, Roland Andersson, Mattias Löhr, Carl A.K. Borrebaeck
• IGF1 receptor is Overexpressed in Metastatic Pancreatic Cancer. Justin S. Huang, Michael E. Egger, William E. Grizzle, Lacey R. McNally
• Inactivation of the orphan nuclear receptor TR3 induces ER stress-mediated apoptosis by increasing ROS production in pancreatic cancer cells. Syng-Ook Lee, Jeong Han Kang, Un-Ho Jin, Aaron S. Guthrie, Sandeep Sreevalsan, Stephen H. Safe
• Induced pluripotent stem cells from pancreatic ductal adenocarcinoma can recapitulate early developmental stages of cancer. Jungsun Kim, Kenneth S. Zaret, John P. Hoffman, Maximilian Reichert, Andrew D. Rhim, Ben Z. Stanger, Andrew Gumbs
• Inhibition of stromal derived CTGF sensitizes murine pancreatic adenocarcinoma to gemcitabine treatment. Albrecht Neesse, Kristopher K. Frese, Tash E. Bapiro, Suzanne Spong, Duncan I. Jodrell, David A. Tuveson
• Inhibition of the malignant phenotype in pancreatic ductal adenocarcinoma (PDAC) cells by PRL-2 siRNA. Pamela L. Crowell
• Investigating the role of nuclear FGF2 signalling in pancreatic cancer. Stacey Coleman, Hemant Kocher, Richard Grose
• JAK2 inhibition blocks STAT3 signaling and enhances drug delivery and therapeutic response in pancreatic cancer. Nagaraj Nagathihalli, Yugandhar Beesetty, Michelle Reyzer, Chanjuan Shi, Richard Caprioli, Nipun Merchant
• Knockdown of STAT3 inhibits growth and enhances response to gemcitabine in an orthotopic model of human pancreatic cancer. Lindsay L. Peterson, Shujie Zhao, Venkatasubbarao Kolaparthi, James W. Freeman
• KRASG12D- and BRAFV600E-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Victoria Appleman, Leanne Ahronian, JiuFeng Cai, David Klimstra, Brian Lewis
• Loss of the Hippo Pathway Effector Yap Disrupts Pancreatic Morphogenesis and Exacerbates Exocrine Pancreatitis. Sonal Gupta, Anirban Maitra, Ji-Kon Ryu, Nailing Zhang, Seungmin Bang, Meritxell Rovira, Hanno Matthaei, Seung-Mo Hong, Steven D. Leach, Duojia Pan
• Macropinocytosis as a mechanism of amino acid supply. Cosimo Commisso, Shawn M. Davidson, Rengin G. Soydaner-Azeloglu, Seth J. Parker, Christian M. Metallo, Matthew G. Vander Heiden, Dafna Bar-Sagi
• MAPK signaling mediates Kras-driven PanIN formation and maintenance. Meredith A. Collins, Yaqing Zhang, Sabita Rakshit, Judith S. Sebolt-Leopold, Marina Pasca di Magliano
• MEK1/2 inhibition with the novel chemotherapeutic agent BAY 86-9766 (RDEA119) – a promising treatment strategy for pancreatic cancer. Nicole Teichmann, Marija Trajkovic-Arsic, Arne Scholz, Schmid M. Roland, Braren Rickmer, Jens T. Siveke
• Metastasis-associated loci in pancreatic cancer identified using Sleeping Beauty insertional mutagenesis. Karen M. Mann, Nancy A. Jenkins, Neal G. Copeland
• miRNA expression differs between African American and European American patients with pancreatic adenocarcinoma. Lacey R. McNally, Elizabeth H. Kerr, Denise Oelschlager, Cecil Stockard, William E. Grizzle
• Pancreatic Cancer Tumor Initiating Cells are Marked by the Presence of Cell Surface Associated Acetylated Alpha Tubulin. Jennifer M. Bailey, Janivette Alsina, Florencia McAllister, Zeshaan Rasheed, Anirban Maitra, William Matsui, Steven Leach
• Pancreatic Ductal Adenocarcinoma Can Arise from Nestin-Positive Progenitor Cells in the Adult Pancreas. Hideaki Ijichi, Koji Miyabayashi, Motohisa Tada, Dai Mohri, Ryoichiro Kageyama, Masao Omata, Kazuhiko Koike, Harold L. Moses
• Potential interactions of gene variants of genes in inflammation pathways and anti-inflammatory medications with risk of pancreatic cancer. Kaye M. Reid Lombardo, Xiang-Lin Tan, William R. Bamlet, Dennis P. Robinson, Brooke L. Fridley, Ann L. Oberg, Kristin E. Anderson, Gloria M. Petersen
• Primary tumor xenograft establishment from pancreatic resection specimens. Emin Ibrahimov, Nhu-An Pham, Fannong Meng, Mayleen Sukhram, Dianne Chadwick, Stefano Serra, Patricia Shaw, Corwyn Rowsell, Calvin Law, John McPherson, Steven Gallinger, Ming-Sound Tsao
• Protease-activated receptor 2 in the microenvironment drives lymphangiogenesis and subsequent lymphe metastasis in a murine pancreatic cancer model. Kun Shi, Karla C.S. Queiroz, C. Arnold Spek
• Protein kinase C zeta plays an important role in the oncogenic phenotype of pancreatic cancer cells. Amanda M. Butler, Michele L. Scotti, Shuhua Li, Alan P. Fields, Nicole R. Murray
• Proteomic Analysis of Cyst Fluids from Intraductal Papillary Mucinous Neoplasms. Lisa J. Zimmerman, Cristina R. Ferrone, Nipun Merchant, Robbert J. C. Slebos, Daniel C. Liebler
• Proteomic analysis of perineural invasion in pancreatic ductal adenocarcinoma. Wasfi Alrawashdeh, Richard Jones, Pedro Cutillas, Nilukshi Wijesuriya, Tatjana Crnogorac-Jurcevic
• Role of the ductal transcription factors HNF6 and Sox9 in pancreatic neoplasia. Adrien Grimont, Géraldine Van den Steen, Frédéric P Lemaigre, Patrick Jacquemin
• RON overexpression drives macrophage differentiation toward an alternatively activated (M2) phenotype in a mouse model of spontaneous pancreatic carcinogenesis. Michele L. Babicky, Megan M. Harper, Evangeline Mose, Dawn Jaquish, Randall French, Andrew M. Lowy
• SIAH-dependent SMAD2/3/4 Ubiquitination and Degradation in Mediating the K-RAS-TGFβ Antagonism during Tumorigenesis and Metastasis in Human Pancreatic Cancer Cells. Amy H. Tang, Yang Liao, Maryanne Edens, Ralf Janknecht, Edward B. Leof
• SLC6A14, an amino acid transporter, is a novel and effective drug target for treatment of pancreatic cancer. Veena Coothan Kandaswamy, Prasad D. Puttur, Muthusamy Thangaraju, Vadivel Ganapathy
• Targeting metabolic reprogramming in hypoxic models of pancreatic cancer: Preclinical emergence of novel LDH inhibitors, molecular mechanisms underlying their synergistic interaction with gemcitabine. Amir Avan, Rocco Sciarrillo, Carlotta Granchi, Niccola Funel, Richard J. Honeywell, Marco Macchia, Filippo Minutolo, Godefridus J. Peters, Elisa Giovannetti
• Targeting Notch signaling with a dual Notch 2/3 antagonist, OMP-59R5, inhibits tumor growth and decreases cancer stem cell frequency in pancreatic cancer. Wan-Ching Yen, Marcus Fischer, Aaron Sato, Min Wang, Ann M. Kapoun, John Lewicki, Austin Gurney, Timothy Hoey
• Targeting pancreatic cancer stroma with Histone Deacetylase Inhibitors. Mohammed Ayman Ghallab, Rosignoli Guglielmo, Irene Sangrador Escrig, Ian R. Hart, Satya Bhattacharya, Hemant M. Kocher
• Targeting Tumor Initiating Cells in Patient-Derived Pancreatic Xenograft Models Using the Hypoxia-Activated Prodrug TH-302. Ines Lohse, Joanna Rasowski, Emin Ibrahimov, Richard Hill, Ming S. Tsao, David W. Hedley
• The evaluation of the synthetic triterpenoid CDDO-ethyl amide and the histone deacetylase inhibitor vorinostat for prevention of pancreatic cancer. Karen Liby, Darlene Royce, Charlotte Williams, Renee Risingsong, Kim Tran
• The HMGB1/RAGE Inflammatory Pathway Promotes Pancreatic Tumor Growth by Regulating Mitochondrial Bioenergetics. Rui Kang, Daolin Tang, Nicole E. Schapiro, Michael T. Lotze, Herbert J. Zeh
• The need for Advocacy for Pancreatic Cancer to raise awareness, increase funding for Research and the need for a Early Detection Protocol. Michele M. Powers
• The proportion of pancreatic stellate cells plays a critical role in modulating pancreatic cancer cell behaviour. Raghu Kadaba, Hanna Birke, Francesco DiMaggio, Jun Wang, Claude Chelala, Peter Sasieni, Hemant M. Kocher
• The role of Hes1 in Pancreatic Ductal Adenocarcinoma (PDAC) development. Roxanne Leontine Brodylo, Clara Lubeseder-Martellato, Bence Sipos, Pawel K. Mazur, Alexander Herner, Roland M. Schmid, Jens T. Siveke
• The Role of Insulin receptor and Insulin-like growth factor I receptor in Pancreatic ductal adenocarcinoma. Evdokia Kalideris, Barbara Grüner, Marija Trajkovic-Arsic, Roxanne Brodylo, Roland Schmid, Jens Siveke
• The role of Pim kinases and RUNX transcription factors as potential molecular targets of K-Ras signaling in pancreatic cancer cells. Michael G. Cobb, Dana M. Austin, Dapeng Xu, Antonio T. Baines
• The use of mouse models of pancreatic cancer to evaluate sensitivity to targeted therapies. Jennifer P. Morton, Douglas C. Morran, Saadia A. Karim, Nigel B. Jamieson, T.R. Jeffry Evans, Owen J. Sansom
• Thrombin-driven signalling induces pancreatic cancer cell survival. Karla C.S. Queiroz, Therese Liechtenstein, Kun Shi, C. Arnold Spek
• Toward targeting integrin αvβ6 for the therapy of pancreatic cancer. Sabari Vallath, Emaunela Gadaletta, Claude Chelala, Aldo Scarpa, Ian R. Hart, Hemant M. Kocher, John F. Marshall
• Transnuclear mice from pancreatic tumor infiltrating T cells. Stephanie K. Dougan, Angelina Bilate, Hidde Ploegh
• Tumor-associated pancreatic metaplasia assumes a biliary duct-like phenotype. Kathleen E. DelGiorno, Kenneth Takeuchi, Christopher Halbrook, Howard C. Crawford
• Using in vivo phage display to discover novel, non-vascular endothelial growth factor (VEGF) mediated tumor angiogenic proteins such as hornerin. Marc E. Seaman, Kimberly A. Kelly
• Validation and exploration of an isogenic cell line panel for pancreatic ductal adenocarcinoma. Fabian Echterdiek, Rainer Will, Oliver Strobel, Jens Werner, Markus Büchler, Stefan Wiemann, Rienk Offringa
• Validation of a panel of candidate pancreatic cancer serum biomarkers identifies SYCN and REG1B to significantly improve the performance of CA19.9. Shalini Makawita, Apostolos Dimitromanolakis, Antoninus Soosaipillai, Ireena Soleas, Alison Chan, Steven Gallinger, Randy S. Haun, Ivan Blasutig, Eleftherios P. Diamandis
• Whole genome mutation landscape in Pancreatic Ductal Adenocarcinoma. Carson Holt, Fouad Yousif, Lee Timms, Michelle Sam, Kimberly Begley, Thomas Hudson, John D. McPherson, Lincoln D. Stein, Lakshmi B. Muthuswamy, Christina Yung, Tim Beck, Bojan Losic, Niloofar Arshadi, Christine Ouelltt, Irinia Kalatskaya, Richard de Borja, Robert Denroche
• Wnt7B mediates high levels of autocrine Wnt/β-catenin signaling in pancreatic adenocarcinoma. Michael D. Arensman, Anne N. Kovochich, Anna R. Lay, Rima M. Kulikauskas, Andy J. Chien, David W. Dawson
• WR1 induces cell hyperproliferation via Myc transactivation in pancreatic cancer. Han-Cheon Kim, Jae-Il Park